FMP
VolitionRx Limited
VNRX
AMEX
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texas.
0.475 USD
-0.0125 (-2.63%)
VNRX Financial Statements
Year
2024
2023
2022
2021
Current Assets
4.06M
21.85M
12.17M
21.98M
Cash & Short Term Investments
3.26M
20.73M
10.87M
20.58M
Cash And Cash Equivalents
3.26M
20.73M
10.87M
20.58M
Short Term Investments
0
0
0
0
Net Receivables
110.57k
242.62k
72.61k
12.51k
Inventory
0
0
784.92k
598.37k
Other Current Assets
343.14k
360.13k
447.57k
786.64k
Non-Current Assets
5.34M
6.1M
6.12M
5.51M
Property, Plant & Equipment
5.03M
6.07M
6.01M
5.29M
Goodwill And Intangible Assets
313.75k
23.89k
110.5k
216.88k
Goodwill
0
0
0
0
Intangible Assets
313.75k
23.89k
110.5k
216.88k
Long Term Investments
0
0
0
0
Tax Assets
0
0
0
0
Other Non-Current Assets
0
0
-6.12M
-5.51M
Other Assets
0
0
0
0
Total Assets
9.4M
27.95M
18.3M
27.49M
-
-
-
-
Current Liabilities
7.79M
31.84M
17.39M
6.52M
Accounts Payable
2.77M
3.21M
3.04M
1.54M
Short Term Debt
1.13M
1.21M
1.36M
1.02M
Tax Payables
0
0
0
0
Deferred Revenue
230k
23M
10M
12.51k
Other Current Liabilities
188.95k
242.13k
-291.18k
-207.61k
Total Current Liabilities
7.79M
31.84M
17.39M
6.52M
Total Non-Current Liabilities
27.72M
4.83M
4.04M
3.25M
Long-Term Debt
3.95M
3.62M
3.62M
3M
Deferred Revenue
0
0
0
0
Deferred Taxes Liabilities
0
0
0
0
Other Non Current liabilities
23.76M
422.71k
-415.76k
-475.17k
Total Liabilities
35.51M
36.66M
21.42M
9.77M
Other Liabilities
0
0
0
0
Stockholders Equity
-24.91M
-7.8M
-2.57M
17.94M
Common Stock
0
81.9k
57.87k
53.77k
Retained Earnings
-229.54M
-202.58M
-167.26M
-136.99M
Accumulated Other Comprehensive Income/Loss
385.63k
243.94k
227.1k
148.33k
Other Shareholders Equity
204.25M
0
0
0
Total Liabilities and Stockholders Equity
9.4M
27.95M
18.3M
27.49M
Retained Earning Schedule
Year
2024
2023
2022
2021
Retained Earnings (Previous Year)
-202.58M
-167.26M
-136.99M
-110.17M
Net Income
-26.97M
-35.32M
-30.27M
-26.97M
Stock Repurchases
0
-31.77k
0
0
Dividend Paid
0
0
0
0
Retained Earnings
-229.54M
-202.58M
-167.26M
-136.99M
Other Distributions
-26.97M
-35.35M
-30.27M
-26.81M
PPE Schedule
Year
2024
2023
2022
2021
Gross PPE
5.03M
6.07M
6.01M
5.29M
Annual Depreciation
1.34M
1.41M
1.19M
1.15M
Capital Expenditure
-277.5k
-1.08M
-1.57M
-973.56k
Net PPE
3.97M
5.74M
6.39M
5.12M
Intangible and Goodwill Schedule
Year
2024
2023
2022
2021
Acquisitions and Adjustments
0
0
0
0
Goodwill (Previous Year)
0
0
0
0
Goodwill
0
0
0
0
All figures are in USD.
